Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
UBS
Daiichi Sankyo
Farmers Insurance
Fuji
Fish and Richardson
Medtronic
Healthtrust
US Army

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,317,629

« Back to Dashboard

Summary for Patent: 6,317,629
Title: Iontophoretic drug delivery apparatus
Abstract:An iontophoretic delivery device (10) is provided. Device (10) has an electronic circuit (32) having electronic components such as batteries (30) mounted thereon. Device (10) also includes a pair of electrode assemblies (18, 19). The electronic circuit (32) is electrically connected to the electrode assemblies (18, 19) using an electrically conductive adhesive (34). The adhesive can also be used to electrically connect two or more electronic components within circuit (32) or to connect an electronic component to the electronic circuit (32). In one practice of the invention, the electrically conductive adhesive (44) functions as an electrode and electrically connects the circuit (32) to an agent-containing reservoir (24, 25). In a further practice of the invention, the electrically conductive adhesive (93) functions as an agent reservoir and contains the agent to be iontophoretically delivered.
Inventor(s): Haak; Ronald P. (San Jose, CA), Gyory; J. Richard (San Jose, CA), Myers; Robert M. (Menlo Park, CA), Landrau; Felix A. (San Jose, CA), Sanders; Harold F. (La Jolla, CA), Kleiner; Lothar W. (Los Altos, CA), Hearney; Linda M. (Saratoga, CA)
Assignee: Alza Corporation (Mountain View, CA)
Application Number:08/351,381
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 6,317,629

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,317,629

PCT Information
PCT FiledJune 01, 1993PCT Application Number:PCT/US93/05162
PCT Publication Date:December 09, 1993PCT Publication Number: WO93/24178

International Family Members for US Patent 6,317,629

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 4399193 ➤ Try a Free Trial
Canada 2134351 ➤ Try a Free Trial
Germany 69314634 ➤ Try a Free Trial
Denmark 0643600 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Covington
AstraZeneca
US Department of Justice
Citi
Merck
Baxter
US Army
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.